Digital chronic-care leader Omada Health is set to begin prescribing GLP-1 weight-loss drugs nationwide in 2026, marking a major expansion of its obesity-care platform. The move follows White House deals with Eli Lilly and Novo Nordisk to lower drug prices, signaling broader public access.
Omada’s GLP-1 program—already supporting over 100,000 members—combines prescribing with AI-driven coaching, nutrition guidance, and remote monitoring. New data show that 63% of members maintained or continued losing weight a year after stopping GLP-1s when paired with Omada’s behavior-change model.